RNXT Share Price Performance
US$1.02
-0.35 (-25.55%)
91.8% undervalued intrinsic discount
US$12.50
Fair Value
Price US$1.02
AnalystHighTarget US$12.50
Stock_Research_Today US$4.20
AnalystLowTarget US$2.75
Fair ValueUS$12.50
Share Pricen/a
RenovoRx, Inc. Stock Price
- 4 Narratives written by author
- 3 Comments on narratives written by author
- 242 Fair Values set on narratives written by author
RNXT Community Narratives
AN
Fair Value US$12.5 91.8% undervalued intrinsic discount
Targeted Cancer Drug Delivery Will Reshape Long Term Potential For This Undervalued TAMP Platform
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ST
Fair Value US$4.2 75.7% undervalued intrinsic discount
Revolutionizing Cancer Treatment
17users have liked this narrative
3users have commented on this narrative
129users have followed this narrative
AN
Fair Value US$2.75 62.9% undervalued intrinsic discount
TIGeR PaC Dependency And Slow Adoption Will Challenge This Solid Tumor Bet Long Term
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.Read more
7.5k
users have viewed this narrative17users have liked this narrative
3users have commented on this narrative
129users have followed this narrative
ST
US$4.2
75.7% undervalued intrinsic discount
Stock_Research_Today's Fair Value
Revenue
371.3% p.a.
Profit Margin
36%
Future PE
15x
Price in 2029
US$3.98
TIGeR PaC Dependency And Slow Adoption Will Challenge This Solid Tumor Bet Long Term
Catalysts About RenovoRx RenovoRx is a medical technology company focused on targeted intra-arterial drug delivery for treating solid tumors, including locally advanced pancreatic cancer. What are the underlying business or industry changes driving this perspective?Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2.75
62.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
188.34% p.a.
Profit Margin
16.72%
Future PE
33.53x
Price in 2029
US$3.38
Targeted Cancer Drug Delivery Will Reshape Long Term Potential For This Undervalued TAMP Platform
Catalysts About RenovoRx RenovoRx develops and commercializes TAMP enabled by the RenovoCath device for targeted intra-arterial delivery of chemotherapy to solid tumors. What are the underlying business or industry changes driving this perspective?Read more
25
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$12.5
91.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
363.65% p.a.
Profit Margin
42.44%
Future PE
14.42x
Price in 2029
US$15.35
Targeted Oncology Platform Will Drive Expanding Treatment Adoption Over The Coming Years
Catalysts About RenovoRx RenovoRx is a clinical stage medical technology company developing targeted intra arterial drug delivery solutions for difficult to treat solid tumors. What are the underlying business or industry changes driving this perspective?Read more
30
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$5.56
81.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
267.15% p.a.
Profit Margin
24.83%
Future PE
22.12x
Price in 2028
US$6.82
Trending Discussion
Recently Updated Narratives
ST
Revolutionizing Cancer Treatment
Fair Value: US$4.2 75.7% undervalued intrinsic discount
129 followersusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TIGeR PaC Dependency And Slow Adoption Will Challenge This Solid Tumor Bet Long Term
Fair Value: US$2.75 62.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Targeted Cancer Drug Delivery Will Reshape Long Term Potential For This Undervalued TAMP Platform
Fair Value: US$12.5 91.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
RenovoRx, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.30
- 67.78%
- -1,196.66%
- 0%
About RNXT
- Founded
- 2009
- Employees
- 10
- CEO
- WebsiteView website
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
